Dare Bioscience, Inc. (DARE)
Nasdaq: DARE · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2007
Who owns Dare Bioscience, Inc.
As filed with the SECHolders of 5% or more
3
L1 Capital Global Opportunities Master Fund, Ltd. holds 9.99% of Common Stock, $0.0001 par value, as its SCHEDULE 13G filed Aug 24, 2026 says.
Directors and officers
7
report now, of 25 people on the record since 2014. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
L1 Capital Global Opportunities Master Fund, Ltd.
SCHEDULE 13G · filed Aug 24, 2026 · Common Stock, $0.0001 par value
Lind Global Fund III LP
SCHEDULE 13G · filed Aug 28, 2026 · Common Stock, $0.0001 par value
Law Custodial Inc.
SCHEDULE 13G/A · filed Dec 23, 2025 · Ordinary Shares · 15.9% in Oct 6, 2025
What DARE reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Mbi
An entity · legal entity · owns, named in the 10-K filed Mar 26, 2026
4 subsidiaries in 2 countries, from the list filed with the 10-K filed Mar 26, 2026.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2019 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.